Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Setmelanotide (Imcivree) Peptide
MC4R agonist for rare genetic obesity disorders.
What is Setmelanotide (Imcivree)?
Setmelanotide (Imcivree) is a melanocortin agonist · metabolic peptide studied for pomc/lepr/pcsk1 deficiency obesity and bardet–biedl syndrome. Below is an educational overview of Setmelanotide (Imcivree) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Imcivree
Obesity caused by certain rare genetic conditions (POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome).
A daily injection that turns on a specific brain hunger switch (MC4R) that is broken in some rare genetic disorders.
- •Skin darkening (hyperpigmentation)
- •Injection-site reactions
- •Nausea
- •Headache
- •Dark spots on face/body
- •Spontaneous penile erections / sexual side effects
- •Depression and suicidal thoughts
- •Skin cancer risk (skin screening recommended)
- •History of melanoma
- •Premature infants (contains benzyl alcohol)
- •History of depression/suicidality (caution)
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Setmelanotide (Imcivree) Mechanism of Action
Cyclic 8-amino-acid melanocortin-4 receptor (MC4R) agonist that restores signaling in the leptin–melanocortin pathway, addressing hyperphagia and obesity in specific genetic deficiencies (POMC, PCSK1, LEPR, Bardet–Biedl syndrome).
Setmelanotide (Imcivree) Research Areas & Benefits
Setmelanotide (Imcivree) Dosage & Common Research Protocols
1–3 mg SC daily, titrated; pediatric dosing available.
Protocols summarized for educational reference from published research. Not dosing guidance.
Setmelanotide (Imcivree) Studies & Cited Research
Setmelanotide phase 3 trials
Significant weight loss and hunger reduction in genetic obesity syndromes.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Setmelanotide (Imcivree) Side Effects & Safety Considerations
- •FDA-approved.
- •Hyperpigmentation, injection-site reactions common.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.